Last reviewed · How we verify
Sequential CTX — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Sequential CTX (Sequential CTX) — RemeGen Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sequential CTX TARGET | Sequential CTX | RemeGen Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sequential CTX CI watch — RSS
- Sequential CTX CI watch — Atom
- Sequential CTX CI watch — JSON
- Sequential CTX alone — RSS
Cite this brief
Drug Landscape (2026). Sequential CTX — Competitive Intelligence Brief. https://druglandscape.com/ci/sequential-ctx. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab